Neuroplasticity Enhancements are Driving Advancements in Brain Health

Author : Purvaja Jadhao | Published On : 18 Jan 2024

Neuroplasticity refers to the brain's ability to form, strengthen, and reorganize connections between neurons as a result of learning, development, damage, or impairment. The global neuroplasticity industry has grown steadily due to advancements in neuroscience research demonstrating the potential for neuroplastic changes throughout the lifespan. Neuroplasticity-based therapies aim to enhance cognitive abilities or restore lost function through targeted exercises, stimulation techniques, or pharmacologic interventions. As life expectancies increase worldwide, the market demand for solutions to optimize brain health, delay aging-related decline, and treat neurological disorders will continue rising rapidly.

The increasing prevalence of conditions like stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and other degenerative conditions are driving substantial interest and investment in neuroplasticity-enhancing therapies. Globally, over 50 million people are living with dementia, costing an estimated $1 trillion annually in social and economic burdens. Neuroplasticity offers hope that some cognitive losses may be mitigated or reversed through lifestyle modifications and targeted interventions. Noninvasive brain stimulation techniques like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are gaining popularity for their ability to enhance cognitive functions like attention, memory, and executive functions without the risks of surgery. Digital therapeutic applications utilizing cognitive training exercises are also proliferating as a prescription digital therapeutic or over-the-counter brain health tool. The global Neuroplasticity Market is estimated to be valued at US$ 6.61 Bn in 2023 and is expected to exhibit a CAGR of 27.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the neuroplasticity market is the increasing adoption of digital therapeutics and digital brain training applications. With widespread internet and smartphone access, digital platforms provide a low-cost and highly scalable means of delivering neuroplasticity-enhancing cognitive exercises, stimulation, and interventions. Popular brain training apps like Elevate, Lumosity, and CogniFit have millions of users and clinical studies support their efficacy in improving cognitive abilities. As evidence for their benefits accumulates, insurance reimbursement and inclusion of digital therapeutics in integrated care models will further accelerate adoption. These platform innovations are extending neuroplasticity-based therapies to broader populations and driving significant market expansion.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as clinical trials are required to introduce new products. However, increasing focus on neuroplasticity presents opportunities.

Bargaining power of buyers: The bargaining power of buyers is moderate as multiple companies operate in the market providing options. However, specialty and novel products command premium pricing.

Bargaining power of suppliers: The bargaining power of suppliers is low as raw materials include common chemicals and there are many suppliers. However, key players can influence prices.

Threat of new substitutes: The threat of new substitutes is low as neuroplasticity drugs do not have effective substitutes for various CNS conditions.

Competitive rivalry: Competition is high as major players focus on innovations, manufacturing expansion, and marketing partnerships to gain market share.

Key Takeaways
The Global Neuroplasticity Market Demand is expected to witness high growth. Regional analysis comprises North America dominates the market due to advanced healthcare facilities and spending. Europe holds the second largest share owing to increasing geriatric population and neurodegenerative diseases. Asia Pacific exhibits lucrative potential for neuroplasticity companies due to improving healthcare infrastructure and rising medical tourism.

Key players operating in the neuroplasticity market include Pfizer, Merck, Novartis, Johnson & Johnson, Biogen, TEVA Pharmaceutical Industries, Eli Lilly and Company, GSK, AstraZeneca, Shire, and others. Key players focus on collaborative research for developing novel neuroplasticity drugs. Companies also pursue inorganic growth strategies such as acquisitions to strengthen product portfolios.

For more insights, Read- https://www.insightprobing.com/neuroplasticity-market-demand-share-analysis/